ABVX:EPA
Abivax SA
97,95 €
arrow_upward
+0,36%(+0,35) 1 d
7 sep., 17:35:29 GMT+2 · EUR
search
Alla symboler
1 d
5 d
1 m
6 m
Hittills i år
1 år
5 år
MAX
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för ABVX …
Öppen
98,90 €
Högt
100,80 €
Lågt
97,10 €
Börsvärde
8,55 md
Genomsn. vol.
145,65 tn
Volym
88,80 tn
52v högst
139,00 €
52v lägst
60,45 €
EPS
−4,49 €
Utestående aktier
87,25 mn
Antal anställda
80
Öppen
98,90 €
Högt
100,80 €
Lågt
97,10 €
Börsvärde
8,55 md
Genomsn. vol.
145,65 tn
Volym
88,80 tn
52v högst
139,00 €
52v lägst
60,45 €
EPS
−4,49 €
Utestående aktier
87,25 mn
Antal anställda
80
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Om Abivax SA
VdMarc de Garidel | Hartmut J. Ehrlich
Anställda80
Grundades4 dec. 2013
Huvudkontor-
Sektor-
Webbplatsabivax.com